[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621763":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":95,"collaborators":97,"id":100,"slug":19,"hasResults":101,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":19,"eligibilityCriteria":105,"healthyVolunteers":101,"sex":106,"minAge":107,"maxAge":19,"enrollmentInfo":108,"targetDuration":19,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},{"fullName":5,"class":6},"Zai Lab (Hong Kong), Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ZL-6201","EXPERIMENTAL","ZL-6201 as a single agent",[13],"Drug: ZL-6201",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","ZL-6201 as a single-agent",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"ZL-6201-001 Study Team","CONTACT","(510)-316-3502","ZL-6201-001@zailaboratory.com",[27,40,50,63,73,82],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":19},"Zai Lab Site 02003","RECRUITING","Los Angeles","California","90007","United States",{"type":35,"coordinates":36},"Point",[37,38],-118.24368,34.05223,{"lat":38,"lon":37},{"facility":41,"status":29,"city":42,"state":43,"zip":44,"country":33,"cosmosGeoPoint":45,"geoPoint":49,"contacts":19},"Zai Lab Site 02030","New Haven","Connecticut","06510",{"type":35,"coordinates":46},[47,48],-72.92816,41.30815,{"lat":48,"lon":47},{"facility":51,"status":29,"city":52,"state":53,"zip":54,"country":33,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Zai Lab Site 02026","Sarasota","Florida","34232",{"type":35,"coordinates":56},[57,58],-82.53065,27.33643,{"lat":58,"lon":57},[61],{"name":62,"role":23,"phone":19,"phoneExt":19,"email":19},"Site 02026",{"facility":64,"status":29,"city":65,"state":66,"zip":67,"country":33,"cosmosGeoPoint":68,"geoPoint":72,"contacts":19},"Zai Lab Site 02005","St Louis","Missouri","63160",{"type":35,"coordinates":69},[70,71],-90.19789,38.62727,{"lat":71,"lon":70},{"facility":74,"status":29,"city":75,"state":75,"zip":76,"country":33,"cosmosGeoPoint":77,"geoPoint":81,"contacts":19},"Zai Lab Site 02002","New York","10065",{"type":35,"coordinates":78},[79,80],-74.00597,40.71427,{"lat":80,"lon":79},{"facility":83,"status":29,"city":84,"state":85,"zip":86,"country":33,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Zai Lab Site 02006","Fairfax","Virginia","22031",{"type":35,"coordinates":88},[89,90],-77.30637,38.84622,{"lat":90,"lon":89},[93],{"name":94,"role":23,"phone":19,"phoneExt":19,"email":19},"Site 02006",{"type":96,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[98],{"name":99,"class":6},"Zai Lab (US) LLC","100621763",false,"NCT07374848","Phase 1a\u002Fb Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors","An Open-label, Phase 1a\u002Fb, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors","Inclusion Criteria:\n\n* Adult men and women ≥18 years of age at the time of signing the ICF with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy \\> 3 months\n* Participants must have histologically confirmed and documented diagnosis of locally advanced unresectable and\u002For metastatic sarcoma or a selected solid tumor\n* Participants must be willing to undergo a tumor biopsy prior to start of treatment or provide archived tumor tissue sample\n* Participants with sarcoma should have received no more than 2 lines of previous systemic therapies in the metastatic setting\n* Participants with selected epithelial solid tumors should have received no more than 3 lines of previous systemic therapy in the metastatic\u002Frelapsed refractory setting\n* Participants must have at least one measurable target lesion as defined by RECIST v1.1\n* Adequate organ and marrow function as listed per protocol\n* Must be negative for HIV, HBV, and HCV\n\nExclusion Criteria:\n\n* Participants with another known malignancy that has required treatment within the last 2 years\n* Symptomatic central nervous system (CNS) metastasis, and\u002For those requiring therapy with corticosteroids or anticonvulsants to control associated symptoms\n* Participants with leptomeningeal metastasis\n* Most recent systemic anti-cancer treatment or investigational products\u002Fdevices less than 3 weeks\n* Prior treatment with a topoisomerase-1 inhibitor antibody drug conjugate\n* Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment\n* Clinically significant pulmonary disease including autoimmune, connective tissue, or inflammatory conditions\n* Pregnant or nursing (lactating) women","ALL","18 Years",{"count":109,"type":110},180,"ESTIMATED","INTERVENTIONAL",[113],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.",[116,117],"Solid Tumors","Sarcomas",[119,116,120,121,122],"Sarcoma","Phase1","Antibody-Drug Conjugate (ADC)","Leucine-Rich Repeat-Containing protein 15 (LRRC15)","2026-06-18",{"date":125,"type":126},"2026-06-22","ACTUAL",{"date":128,"type":126},"2026-03-02",{"date":130,"type":110},"2029-09",{"name":132,"class":6},"Zai Lab (Shanghai) Co., Ltd.",6]